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Summary Objective: Plasma concentrations of superantigens were measured in an
intensive care unit (ICU) population and the relationship of superantigen positive rates
with the presence of sepsis was investigated.
Methods: Plasma samples were collected at least twice a week from 78 patients
whose primary diagnoses were abdominal disorders (n = 27), respiratory disorders (n
= 11), trauma (n = 10), burns (n = 10), cardiovascular disorders (n = 4), neurological
disorders (n = 2), and others (n = 14). Five different species of superantigens, i.e.,
staphylococcal enterotoxins A, B, and C (SEA, SEB, and SEC), toxic shock syndrome
toxin-1 (TSST-1), and streptococcal pyrogenic exotoxin A (SPEA), were measured using
an enzyme-linked immunosorbent assay.
Results: Signiﬁcant levels of plasma superantigens were detected in 16 patients.
SEA was found in seven patients, SEB in four patients, SEC in two patients, TSST-1 in
six patients, and SPEA in ﬁve patients. Superantigen detection rates were 6% (1/17)
in patients without systemic inﬂammatory response syndrome (SIRS), 0% (0/21) in
SIRS patients without infection, 31% (5/16) in septic patients without shock, and 42%
(10/24) in septic shock patients.
Conclusions: The presence of superantigens was conﬁrmed in part of the ICU pop-
ulation. The role of superantigens in the pathogenesis of sepsis remains to be deter-
mined.
© 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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Introduction
Sepsis is a major cause of death in patients admit-
ted to intensive care units (ICUs), and the mortality
from septic shock remains unacceptably high at
35—45%.1 It has generally been considered that
sepsis associated with Gram-negative bacterial
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infections is more serious than that with Gram-
positive infections. Recent evidence, however,
suggests that the mortality from Gram-positive
sepsis is comparable with or even greater than that
from Gram-negative sepsis.2 Furthermore, involve-
ment of both Gram-positive and Gram-negative
pathogens is frequently observed in a considerable
number of cases with septic shock.3
Recent studies have focused on the difference
between the pathogenesis of Gram-positive sep-
sis and that of Gram-negative sepsis4—6 and have
suggested the important role of superantigens in
the pathophysiological mechanism of sepsis. A num-
ber of toxins produced by Gram-positive bacteria
have been identiﬁed as superantigens. Such tox-
ins include staphylococcal enterotoxins (SEs: SEA,
SEB, SEC1-3, SED, SEE, SEG, SEH, SEI, and SEJ),
toxic shock syndrome toxin-1 (TSST-1), streptococ-
cal pyrogenic exotoxins (SPEs: SPEA, SPEC, SPEG,
SPEH, SPEJ, and SPEL), and streptococcal mitogenic
exotoxin Z1-2.7—9 These superantigens have been
shown to be potent activators of the immune system
and to cause a variety of diseases in humans, rang-
ing from food poisoning to toxic shock syndrome
(TSS).10,11
Unlike conventional antigens, superantigens are
known to activate T cells through binding to the
class II major histocompatibility complex (MHC) on
antigen presenting cells (APCs) without undergo-
ing the intracellular processing pathway.12 Further-
more, superantigens have been shown to bind to the
 chain variable region (V) of T cell receptor (TCR)
molecules.13 These interactions result in excessive
production of proinﬂammatory cytokines and T cell
proliferation linking to the development of clini-
cal symptoms such as fever and hypotension.14,15
In addition, superantigens have been shown to act
synergistically with lipopolysaccharide to produce
lethal shock.16 Urine and plasma levels of TSST-1
and SPEA have been measured in TSS patients.17—19
The accumulating evidence suggesting the im-
portant role of superantigens in the pathophysiol-
ogy of sepsis prompted the examination of actual
plasma levels of superantigens in patients admit-
ted to ICUs. In this report, plasma levels of SEA,
SEB, SEC, TSST-1, and SPEA in an ICU population are
measured and the relationship between the super-
antigen positive rate and the presence of sepsis is
determined.
Materials and methods
Patients and blood sampling
This study was conducted in the medical and surgi-
cal intensive care units (ICUs) of Chiba-Hokuso Hos-
pital and Sendagi Hospital, Nippon Medical School.
They also function as level 1 trauma centers.
Blood samples were obtained from 22 consecutive
septic patients who were admitted to the ICU of
Chiba-Hokuso Hospital between October 1997 and
January 1999, and from 56 consecutive patients
admitted to the ICU of Sendagi Hospital between
October 1998 and February 1999. Patients with
cancer, immunodeﬁciency, a cardiovascular disor-
der such as coronary disease, or a serious chronic
disease were excluded from the study. The diag-
nosis of systemic inﬂammatory response syndrome
(SIRS), sepsis and septic shock was determined,
based on the criteria recommended by the Ameri-
can College of Chest Physicians/Society of Critical
Care Medicine Consensus Conference Committee.20
Blood sampling from each patient was performed
at least twice a week. The collected blood samples
were centrifuged at 3000 rpm and 4 ◦C for 15mins.
Each plasma sample was divided into aliquots,
then immediately frozen, and kept at −80 ◦C until
use. When an increase in body temperature, white
blood cell count, or C-reactive protein level was
detected, cultures of blood, pulmonary aspirate,
urine, and/or other sites of possible sources of
infection were obtained.
The enzyme-linked immunosorbent assay used in
this study for determining plasma levels of super-
antigens was expected to be sensitive enough and to
require no extra blood sampling except for routine
examination for hematology and clinical chemistry.
Considering these conditions, the Ethics Committee
on Research at both hospitals concluded that it was
unlikely that patients would be exposed to addi-
tional risk due to their enrollment. The committee
also conﬁrmed that the treatment andmanagement
of the enrolled patients was completely indepen-
dent of the results of the serological screening. Un-
der these circumstances, the committee concluded
that it was not necessary to obtain written informed
consent from each patient, but recommended that
the patients should be provided with sufﬁcient in-
formation about this study by the investigators.
Measurement of plasma concentrations of
superantigens
Plasma concentrations of SEA, SEB, SEC, TSST-1
and SPEA were measured at a single labora-
tory by enzyme-linked immunosorbent assay
(ELISA; Toray Industries Inc., Tokyo, Japan).21
In brief, plasma samples were diluted two-fold
and placed in wells of an ELISA plate precoated
with polyclonal antibodies against a superanti-
gen. Each plate was treated with a horseradish
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peroxidase-labeled monoclonal antibody against
the superantigen and then with the substrate,
3,3′,5,5′-tetramethyl-benzidine (Katayama Chemi-
cal, Osaka, Japan). The enzyme reaction was ter-
minated by the addition of 0.1mL of 0.5M sulfuric
acid, and the ELISA plates were read spectropho-
tometrically at 450 nm. Each of the superantigens,
SEA, SEB, SEC, TSST-1 and SPEA, were subjected
to a series of dilutions with buffer containing 2.5%
bovine serum albumin (Seikagaku Corporation,
Tokyo, Japan) and used as standard solutions for
obtaining a calibration curve. The quantitation
limits for SEA, SEB, SEC, TSST-1 and SPEA were
1.4, 5.9, 16.3, 2.5 and 4.3 pg/mL, respectively, in
buffer containing 50% human plasma. A conﬁrma-
tory experiment with puriﬁed samples of SEA, SEB,
SEC, TSST-1 and SPEA indicated no cross-reaction
between any pair of the superantigens at a con-
centration of 800 pg/mL in the ELISA. Additionally,
puriﬁed staphylococcal protein A and streptococcal
protein G did not react with the ELISAs at a con-
centration of 1mg/ml, because the Fc fragment of
monoclonal antibodies was digested by pepsin and
the IgG fraction from rabbit and mouse sera was
supplemented in the dilution buffer.21 The speci-
ﬁcity of ELISAs for staphylococcal toxins was also
conﬁrmed by comparing the data from reverse pas-
sive latex agglutination assay (Denkaseiken, Tokyo,
Japan).21 For evaluating ELISA results, a superanti-
gen positive response was deﬁned as superantigen
levels higher than the respective 99% cut-off values,
at which the chance of giving a positive ELISA re-
sponse in a healthy patient is less than 1%. The 99%
cut-off concentrations of SEA, SEB, SEC, TSST-1 and
SPEA were 6, 50, 70, 25 and 10 pg/mL, respectively.
Table 1 The numbers of patients and plasma samples studied and the positive rates for at least one species of
superantigens.a
Primary diagnosis Number of
patients
Superantigen positive
patients (%)
Number of
samples
Superantigen positive
samples (%)
Cardiovascular disorder 4 1 (25) 40 1 (3)
Respiratory disorder 11 3 (27) 47 5 (11)
Abdominal disorder
Gastrointestinal 18 5 (28) 88 8 (9)
Others 9 4 (44) 105 11 (11)
Neurological disorder 2 0 (0) 7 0 (0)
Trauma 10 1 (10) 50 7 (14)
Burns 10 2 (20) 95 2 (2)
Other disorders 14 0 (0) 42 0 (0)
Total 78 16 (21) 474 34 (7)
a Ninety-nine percent cut-off values were used to determine that signiﬁcant amounts of superantigens were present
in the circulation of patients.
Statistical analysis
The relationship between the superantigen posi-
tive rate and the severity of infection was ana-
lyzed by the Ryan’s test for multiple comparison of
proportions22 without any stratiﬁcation by the sam-
ple number from each patient or by primary diag-
nosis.
Results
Plasma superantigen levels were examined in 78
ICU patients (60 males and 18 females) in total.
These patients were 18—83 years old (median: 52)
and primarily diagnosed with abdominal disorders
(n = 27), respiratory disorders (n = 11), trauma
(n = 10), burns (n = 10), cardiovascular disorders
(n = 4), neurological disorders (n = 2), and others
(n = 14) (Table 1). Signiﬁcantly positive responses
were observed in 34/474 (7%) of the plasma sam-
ples obtained. The superantigen positive samples
were derived from 16 patients who had primary
diagnoses of cardiovascular disorders (n = 1), res-
piratory disorders (n = 3), abdominal disorders (n
= 9) [gastrointestinal (n = 5) and others (n = 4)],
trauma (n = 1), and burns (n = 2). The percent-
age of superantigen positive patients among each
primary diagnosis group ranged from 0 to 44% and
showed no apparent correlation between the posi-
tive rates and primary diagnosis.
From the 16 superantigen positive patients, a
total of 203 plasma samples were obtained and
only 17% of the samples demonstrated signiﬁcantly
positive responses (Table 2). The percentage of
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Table 2 Characteristics of 16 patients whose plasma superantigen concentrations were elevated above 99% cut-off values.
Patient
No.
Sex/Age
(yr)
Primary diagnosis Positive
ratesa (%)
Superantigens detectedb
[Peak concentration (pg/ml)]
Microorganisms isolated
(Sites of infection)
Severity of infection Outcome
Sepsis Septic
shock
MODSc
1 M/75 Cardiovascular 1/6 (17) T[27] S. aureus (Sputum) + + + Alive
2 F/33 Respiratory 2/3 (67) T[26] S. aureus (Sputum) + − − Alive
3 M/50 Respiratory 1/1 (100) A[8], T[35], PA[12] K. pneumoniae (Blood) + + + Dead
4 M/54 Respiratory 2/12 (17) PA[30] S. aureus (Blood), S.pyogenes
(Blood)
+ + − Alive
5 M/52 Abdominal (GI)d 4/15 (27) A[16], B[83], C[78], PA[11] S. aureus (Stool, abscess) + − − Alive
6 M/76 Abdominal (GI) 1/13 (8) A[10] S. aureus (Sputum) + − − Alive
7 M/83 Abdominal (GI) 1/3 (33) T[31] Enterococcus sp.,
Enterobacter sp. (Wound)
+ + − Alive
8 M/76 Abdominal (GI) 1/3 (33) T[27] S. aureus (Wound) + + − Alive
9 M/73 Abdominal (GI) 1/1(100) A[9] Negative − − − Alive
10 M/50 Abdominal (Others) 1/6 (17) PA[18] S. aureus (Wound) + − − Dead
11 M/50 Abdominal (Others) 7/38 (18) A[11], B[147] S. aureus (Blood) + + + Alive
12 M/55 Abdominal (Others) 1/3 (33) B[58] K. pneumoniae (Blood) + + + Dead
13 M/70 Abdominal (Others) 2/17 (12) B[153], T[41], PA[182] S. aureus (Blood, ascites) + − − Alive
14 M/54 Trauma 7/17 (41) A[15] S. aureus (Abscess) + + − Alive
15 M/68 Burns 1/57 (2) A[10] S. aureus (Blood),
P.aeruginosa (Blood)
+ + − Alive
16 M/76 Burns 1/8 (13) C[103] S. aureus (Wound, sputum) + + − Dead
a Positive rates = No. of superantigen positive samples/No. of total samples.
b A: staphylococcal enterotoxin A, B: staphylococcal enterotoxin B, C: staphylococcal enterotoxin C, T: toxic shock syndrome toxin-1, and PA: streptococcal
pyrogenic exotoxin A.
c MODS: multiple organ dysfunction syndrome.
d GI: Gastrointestinal disorders.
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Table 3 Relationship between the severity of infection and superantigen detection rates.a
Severity of infection Superantigen
positive
patientsb/total
patients (%)
Superantigen
positive patientsc/
patients with SA or
SPf infection (%)
Superantigen
positive patientsd/
patients without SA
or SPf infection (%)
Superantigen
positive patientse/
non-survivors (%)
Non-SIRSg 1/17 (6) 0/1 (0) 1/16 (6) 0/4 (0)
SIRS without infection 0/21 (0) 0/0 (0) 0/21 (0) 0/1 (0)
Sepsis without shock 5/16 (31)h 5/9 (56) 0/7 (0) 0/2 (0)
Septic shock 10/24 (42)i 7/15 (47) 3/9 (33) 4/15 (27)
Total 16/78 (21) 12/25 (48) 4/53 (8) 4/22 (18)
a Ninety-nine percent cut-off values were used to detect signiﬁcant concentrations of circulating superantigens.
b Superantigen positive patients in total patients.
c Superantigen positive patients with SA or SP infection.
d Superantigen positive patients without SA nor SP infection.
e Superantigen positive patients in non-survivors.
f SA: Staphylococcus aureus, SP: Streptococcus pyogenes.
g SIRS: Systemic Inﬂamatory Response Syndrome.
h p = 0.02, compared with SIRS without infection.
i p = 0.03, compared with non-SIRS. P = 0.003, compared with SIRS without infection.
superantigen positive samples from individual pa-
tients varied from 2 to 67%, except in cases where
only one sample was available from each of the pa-
tients. These results indicated that a superantigen
positive patient did not always exhibit a positive
response. As for the species of superantigens de-
tected, SEA was demonstrated in seven patients,
SEB in four patients, SEC in two patients, TSST-1 in
six patients, and SPEA in ﬁve patients (Table 2). In
12 patients, only a single species was detected. Pos-
itive responses to multiple species were observed
in the following four patients: four species in pa-
tient no. 5; three species in patient nos. 3 and 13;
and two species in patient no. 11. When biological
samples such as blood, aspirate, urine, and/or ab-
scess, were obtained from the superantigen positive
patients, Staphylococcus aureus was found in the
cultures from 12 patients. The S. aureus-positive
samples included blood samples from four patients.
The isolated bacteria, however, were not further
examined for their capacity to produce superanti-
gens. The frequency of positive reactions from su-
perantigens was 25% (15/60) in male patients and
6% (1/18) in female patients.
Sepsis was conﬁrmed in 15/16 (94%) of the super-
antigen positive patients and septic shock in ten pa-
tients. Four septic shock patients were complicated
by multiple organ dysfunction syndrome. When the
78 patients enrolled in the study were examined,
61 patients (78%) were classiﬁed as having systemic
inﬂammatory response syndrome (SIRS), and 17 pa-
tients (22%) were non-SIRS (Table 3). Among the
61 SIRS patients, 21 patients were diagnosed as
SIRS without infection, 16 patients as sepsis with-
out shock, and 24 patients as septic shock. Super-
antigen positive rates were 6% in non-SIRS, 0% in
SIRS without infection, 31% in sepsis without shock,
and 42% in septic shock. Statistical analysis indi-
cated that the superantigen positive rate in septic
patients without shock was signiﬁcantly higher than
that in SIRS patients without infection, and that
the superantigen positive rate in septic shock pa-
tients was signiﬁcantly higher (p < 0.05) than that
in non-SIRS patients or SIRS patients without infec-
tion.
In the patients whose bacteriological examina-
tion revealed S. aureus and/or Streptococcus pyo-
genes infection, the superantigen positive rate was
48% (56% in septic patients without shock, 47% in
septic shock patients). The positive superantigen
detection rate in patients who showed bacteremia
with S. aureus or S. pyogenes was 57% (4/7) and the
rate in patients who had non-bacteremic infections
with S. aureus or S. pyogenes was 44% (8/18). In
patients where neither S. aureus nor S. pyogenes
infection was conﬁrmed, the superantigen positive
rate was 8% (0% in septic patients without shock,
33% in septic shock patients). Death was observed
in 22 patients among the patients enrolled in this
study. Four of these demonstrated superantigen
positive responses and all four had septic shock.
Discussion
In this study, the plasma concentration of ﬁve
different species of superantigens: SEA, SEB,
SEC, TSST-1, and SPEA was examined in an ICU
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population, using a sensitive enzyme-linked im-
munosorbent assay. SEs and SPEs are known
to have some homology in their amino acid
sequence.8 TSST-1 differs from SEs and SPEs in
amino acid sequence but is similar to toxins of
the SE/SPE family in the overall topology.23,24 The
anti-superantigen antibodies used in the current
study have previously been conﬁrmed to exhibit
no signiﬁcant cross-reactivity with other related
superantigens.21
While this study was conducted in a heteroge-
neous patient population, signiﬁcant concentra-
tions of circulating superantigens were detected
in 34 plasma samples obtained from 16 patients.
The plasma concentrations of staphylococcal su-
perantigens, i.e., SEA, SEB, SEC, and TSST-1, were
higher than 99% cut-off values in six, four, two, and
six patients, respectively. The streptococcal super-
antigen, SPEA, was positive in three patients. The
six patients who had TSST-1 in their circulation did
not clinically demonstrate toxic shock syndrome.
In this study, plasma samples were collected twice
weekly. If a more intensive schedule had been em-
ployed, there is a possibility that more superanti-
gen positive patients might have been detected.
Although it could not be determined which species
of superantigens were more likely to be detected
in the blood of ICU patients, it is noteworthy that
the superantigen positive rates in septic patients
were signiﬁcantly higher than those in non-septic
patients. In the patients whose cultures indicated
S. aureus or S. pyogenes infection, superantigen
detection rates were 56% in septic patients with-
out shock and 47% in septic shock patients. On
the other hand, one-third of septic shock patients
whose cultures demonstrated neither S. aureus nor
S. pyogenes showed superantigenemia.
Furthermore, among the 16 superantigen pos-
itive patients, Gram-positive bacteria were not
isolated in seven patients. As for the reasons, the
limited sensitivity of bacterial culture, inappro-
priate site selection for bacterial culture, leakage
of superantigens into the circulation through the
disrupted mucosal barrier that often develops in
critically ill patients, and the inﬂuence of antibi-
otics on bacterial cultures may have been asso-
ciated. While several papers have reported the
synergistic lethal effect of superantigens,25 mor-
tality and the incidence of septic shock or multiple
organ dysfunction syndrome were not higher in pa-
tients who demonstrated more than two species of
superantigens than in those who showed only one
species, as shown in Table 2. The actual concen-
tration of superantigens also did not correlate with
the severity of infection or outcome. These ﬁndings
may suggest that the appearance of superantigens
in the circulation merely illustrates a phenomenon
without any pathologic meanings.
In conclusion, signiﬁcant levels of superantigens
were detected in the plasma of ICU patients. The
detection rates of superantigens were especially
high in septic patients. Further studies, e.g., an ex-
periment which examines superantigen production
activities in microbes isolated from superantigen
positive patients, will help to determine the role of
superantigens in the pathogenesis of sepsis.
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